Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Schizophrenia
Interventions: Brilaroxazine, Placebo; Drug · Other
Lead sponsor: Reviva Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 690 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more

Conditions: Schizophrenia
Interventions: RISPERDAL CONSTA, Paliperidone palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more

Conditions: Bipolar I Disorder, Psychosis, Schizoaffective Disorder
Interventions: Ketogenic diet, Dietary Guidelines for Americans; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Schizophrenia
Interventions: Placebo, RO5545965, risperidone; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
Interventions: Brexpiprazole, Treatment as Usual; Drug · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more

Conditions: Bipolar Depression
Interventions: Infliximab, Saline; Drug · Other
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Akathisia
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1999
U.S. locations: 2
States / cities: Morganton, North Carolina • University Park, Pennsylvania

Conditions: Schizophrenia
Interventions: Placebo, RO4917838, Standard Antipsychotic Therapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Early Psychosis
Interventions: Levetiracetam Pill, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 3 more

Conditions: Pregnant Women, Psychotropic Drugs
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions: Clozapine, Risperidone; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Garden Grove, California • Oakland, California • Miami, Florida + 6 more

Conditions: Bipolar I Disorder, Schizoaffective Disorder, Psychosis
Interventions: Ketogenic diet; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder, Cognitive Impairment
Interventions: Guanfacine/Tenex; Drug
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York • W. Brentwood, New York

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Telmisartan, Placebo, Clozapine, Olanzapine; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Bipolar Depression
Interventions: Brexpiprazole; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: MK-8189, Placebo, Background AAP Therapy; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Clozapine, treatment as usual; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more

Conditions: Autistic Disorder
Interventions: olanzapine (Zyprexa), Placebo; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 3 Years to 12 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder
Interventions: Lithium, Quetiapine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Birmingham, Alabama • Stanford, California • Boston, Massachusetts + 8 more

Conditions: Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions: Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics; Combination Product · Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Unit of use medication packaging, Mailed reminders to patient when medication refills are due, Note to Mental Health Provider when refill is overdue, Aligning all prescriptions to fall due on same date; Behavioral · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 5
States / cities: San Diego, California • Hines, Illinois • East Orange, Massachusetts + 2 more

Conditions: Schizophrenia
Interventions: Placebo, Paliperidone Palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 18
States / cities: Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more

Conditions: Borderline Personality Disorder
Interventions: Quetiapine Fumarate; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cherry Hill, New Jersey

Search by objective public record fields.

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

R33: Levetiracetam in Early Psychosis

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

National Pregnancy Registry for Psychiatric Medications

Clozapine for Cannabis Use in Schizophrenia

Open Label Extension Study of NCT06221852

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Brexpiprazole for Bipolar Depression

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

A Controlled Study of Olanzapine in Children With Autism

Comparative Effectiveness Study for Bipolar Disorder

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Improving Antipsychotic Adherence Among Patients With Serious Mental Illness

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder